Regeneron Pharmaceuticals, Inc.

Amanda Atanasio

David M Valenzuela

Ka-Man Venus Lai

Guochun Gong

Michael L LaCroix-Fralish

Burcin Ikiz

Jamie M Orengo

Lorah Perlee

Gary Herman

Meagan P O'Brien

Michael L Lacroix-Fralish

The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of birch allergy or allergic disease in a subject by administering to the subject an antibody or antigen-binding fragment thereof that binds Bet v 1, or a cocktail of antibodies or antigen-binding fragments thereof that bind Bet v 1.

Methods of treating allergy using anti-Bet v 1 antibodies

A non-human animal model for neurodegenerative and/or inflammatory diseases is provided, which non-human animal comprises a disruption in a C9ORF72 locus. In particular, non-human animals described herein comprise a deletion of an entire coding sequence of a C9ORF72 locus. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative (e.g., amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig's disease) and frontotemporal dementia (FTD)), autoimmune and/or inflammatory diseases (e.g., SLE, glomerulonephritis) are also provided.

Non-human animals having a disruption in a C9ORF72 locus

Growing community of inventors

Valhalla, NY, United States of America

Amanda Atanasio